EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma
October 20, 2020Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma
Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …
European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit
October 19, 2020Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir
As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …
Pfizer won’t apply for COVID-19 vaccine emergency authorisation until after US election, CEO says
October 19, 2020Sales and Marketing COVID-19, Pfizer, US, Vaccine
The Chief Executive Officer of Pfizer has said that the company will now submit their vaccine for FDA Emergency Use …
UK life sciences industry does not want no-deal Brexit, says ABPI Chief
October 19, 2020Sales and Marketing ABPI, EU, UK, brexit, pharma
Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a no-deal scenario with the European …
Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis
October 19, 2020Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis
Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …
CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis
October 19, 2020Sales and Marketing CHMP, EMA, Janssen, Tremfya
Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …
FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal
October 19, 2020Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma
The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …
NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma
October 16, 2020Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …
Gilead’s remdesivir and three other repurposed drugs have no impact on COVID-19 mortality, WHO study finds
October 16, 2020Medical Communications, Research and Development COVID-19, pharma, remdesivir
Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections, but recent studies …
Five-year-old girl that was part of Lysogene’s gene therapy clinical trial dies
October 16, 2020Medical Communications
A five-year-old girl had died while taking part in Lysogene’s clinical trial investigating its gene therapy. The child was suffering …
‘Long COVID’ could be taking four different forms
October 16, 2020Medical Communications coronavirus, covid symptoms, long covid, symptoms
People experiencing chronic illnesses after COVID-19 infections could be suffering from one of four separate conditions, according to new research. …
Top Ten most popular articles on Pharmafile.com this week
October 16, 2020Medical Communications COVID, herd immunity, top ten, top ten articles
The top ten news stories this week focus on herd immunity, as the Director of the World Health Organization has …
80 researchers argue COVID-19 herd immunity strategy is a “dangerous fallacy” in open letter
October 15, 2020Medical Communications, Research and Development, Sales and Marketing COVID-19
A group of 80 researchers have lent their signatures to an open letter published in the The Lancet under the …
Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis
October 15, 2020Sales and Marketing Mayzent, Novartis, Scotland
Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …
NICE recommends siponimod for treating secondary progressive MS
October 15, 2020Medical Communications
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending siponimod for treating secondary progressive multiple …
FDA approves Regeneron’s antibody Ebola treatment
October 15, 2020Research and Development Ebola, ebola antibody., ebola treatment
The FDA has approved Regeneron’s antibody drug inmazeb for treating Ebola. The treatment works through targeting the glycoprotein on the …
Russia gives regulatory approval to second COVID-19 vaccine after early clinical trials
October 15, 2020Research and Development COVID Vaccine, Vaccine, coronavirus vaccine
Russian President Vladimir Putin announced on Wednesday that regulators had given approval to a second coronavirus vaccine. This new vaccine …
Scottish Medicines Consortium approves Revlimid for two groups of blood cancer patients
October 14, 2020Research and Development Revlimid, SMC
The Scottish Medicines Consortium (SMC) has accepted Revlimid (lenalidomide) for routine use on NHS Scotland for patients with multiple myeloma …
Eli Lilly COVID-19 antibody therapy trial paused over safety concerns
October 14, 2020Research and Development COVID, Eli Lilly, coronavirus
Eli Lilly has stopped enrolling volunteers in clinical trials of its antibody treatment for the novel coronavirus over safety concerns. …
British man suffers from permanent hearing damage after contracting COVID-19
October 14, 2020Research and Development COVID-19, pharma
A 45-year-old man in the UK has been left with permanent hearing damage after being infected with the novel coronavirus, …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
